ARTICLE

FindCenter AddIcon

A Dose of a Hallucinogen from a ‘Magic Mushroom,’ and then Lasting Peace

By Jan Hoffman — 2016

Two studies used psilocybin to see if the drug could reduce depression and anxiety in cancer patients. The results were striking.

Read on www.nytimes.com

FindCenter Post-Image

A Brief History of Psychedelic Psychiatry

In the 1950s a group of pioneering psychiatrists showed that hallucinogenic drugs had therapeutic potential, but the research was halted as part of the backlash against the hippy counterculture.

Article
Mo Costandi
2014
FindCenter AddIcon
FindCenter Post-Image

FDA Calls Psychedelic Psilocybin a 'Breakthrough Therapy' for Severe Depression

The FDA is helping to speed up the process of researching and approving psilocybin, a hallucinogenic substance in magic mushrooms, to treat major depressive disorder (MDD).

Article
Yasemin Saplakoglu
2019
FindCenter AddIcon
FindCenter Post-Image

Inside The Movement To Decolonize Psychedelic Pharma

As Western medicine brings psychedelics into mainstream use, a growing movement is innovating new business models grounded in reciprocity and inclusion.

Article
Carolyn Gregoire
2020
FindCenter AddIcon
FindCenter Post-Image

Experimental Treatments Changed the Course of the AIDS Epidemic; We Need the Same Approach to Mental Illness Today | Commentary

Demand from patients seeking help for their mental illnesses has led to underground use in a way that parallels black markets in the AIDS pandemic. This underground use has been most perilous for people of color, who face greater stigma and legal risks due to the War on Drugs.

Article
Monnica Williams, Morgan Campbell
2021
FindCenter AddIcon
FindCenter Post-Image

The Cost of Exclusion in Psychedelic Research

In the last two decades, researchers have started to reexamine psychedelics for their therapeutic potential. Though initial results seem promising, the research has a significant shortcoming: the lack of racial and ethnic diversity among research teams and study participants.

Article
Xinyuan Chen, Mackenzie Bullard, Christy Duan, Jamilah R. George, Terence Ching, Stephanie Kilpatrick, Jordan Sloshower, Monnica Williams
2020
FindCenter AddIcon
FindCenter Post-Image

Psychedelic Psychotherapy Is Coming: Who Will Be Included?

A new study finds widespread exclusion of minorities in psychedelic research.

Article
Monnica T. Williams
2018
FindCenter AddIcon
FindCenter Post-Image

How Researchers and Advocates of Color Are Forging Their Own Paths in Psychedelic-Assisted Therapy

We’re seeing an explosion of medical research into psychedelics. Psilocybin, or shrooms, to treat major depressive disorder. Ayahuasca, a psychotropic plant medicine from the Amazon, and ibogaine, a potent hallucinogen from Africa, to treat addiction. LSD for anxiety.

Article
Steph Yin
2020
FindCenter AddIcon
FindCenter Post-Image

Study Finds Ketamine Can Help Patients Manage Depression and PTSD

Through this treatment plan, the patient was able to “reconceptualize her trauma” and “was able to move through difficult memories and emotions rather than letting them consume her,” explained U of O associate professor, Monnica Williams.

Article
Hannah Sabourin
2021
FindCenter AddIcon
FindCenter Post-Image

Who Will Benefit From Psychedelic Medicine?

These substances are being touted as a game-changing intervention for mental health. But it’s not clear if their promise will be accessible to all.

Article
Whitney Joiner
2020
FindCenter AddIcon
FindCenter Post-Image

Psychedelics Shown to Ease the Effects of Racial Trauma

A recent study found that even a single positive psychedelic experience may ease mental health symptoms associated with racial trauma experienced by Black, Indigenous, and people of color (BIPOC).

Article
Kristi Pahr
2021
FindCenter AddIcon

EXPLORE TOPIC

Psilocybin